Wojtulewski J A, Walter J, Gray J
Curr Med Res Opin. 1978;5(7):562-6. doi: 10.1185/03007997809109002.
A randomized double-blind trial was carried out in 20 patients with osteoarthrosis of the hip or knee to compare the efficacy and tolerance of treatment with diflunisal or naproxen. During the first 4 weeks, patients received either 250 mg diflunisal or 250 mg naproxen twice daily and this was increased by 250 mg daily in 5 patients on diflunisal and in 3 on naproxen for the second 4 weeks of the trial. The results of subjective assessments made before and at the end of Week 8 showed a trend in favour of diflunisal for improvement of symptoms, except for weight-bearing pain which was improved in only 1 patient in each group. More of the patients receiving diflunisal than naproxen considered treatment to have been satisfactory, and rated their response as equally as good as or better than previous medication. Diflunisal produced significantly high incidence of gastro-intestinal upsets, leading to the withdrawal of 2 patients at Week 4.
对20例髋或膝关节骨关节炎患者进行了一项随机双盲试验,以比较双氟尼酸或萘普生治疗的疗效和耐受性。在试验的前4周,患者每日两次服用250mg双氟尼酸或250mg萘普生,在试验的第二个4周,服用双氟尼酸的5例患者和服用萘普生的3例患者每日剂量增加250mg。在第8周开始和结束时进行的主观评估结果显示,除负重疼痛外,在症状改善方面有倾向于双氟尼酸的趋势,每组仅1例患者的负重疼痛得到改善。与服用萘普生的患者相比,更多服用双氟尼酸的患者认为治疗令人满意,并将他们的反应评为与之前的药物相当或更好。双氟尼酸导致胃肠道不适的发生率显著较高,导致2例患者在第4周退出试验。